DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,840,869 B2 Friedman Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,840,869 B2 Friedman Et Al USOO8840869B2 (12) United States Patent (10) Patent No.: US 8,840,869 B2 Friedman et al. (45) Date of Patent: Sep. 23, 2014 (54) BODY CAVITY FOAMS (56) References Cited (75) Inventors: Doron Friedman, Karmei Yosef (IL); U.S. PATENT DOCUMENTS Alex Besonov, Rehovet (IL); Dov 1,159,250 A 11/1915 Moulton Tamarkin, Maccabim (IL); Meir Eini, 1,666,684 A 4, 1928 Carstens Ness Ziona (IL) 1924,972 A 8, 1933 Beckert 2,085,733. A T. 1937 Bird (73) Assignee: Foamix Ltd., Rehovot (IL) 2,390,921 A 12, 1945 Clark 2,524,590 A 10, 1950 Boe 2,586.287 A 2/1952 Apperson (*) Notice: Subject to any disclaimer, the term of this 2,617,754 A 1 1/1952 Neely patent is extended or adjusted under 35 2,767,712 A 10, 1956 Waterman U.S.C. 154(b) by 1533 days. 2.968,628 A 1/1961 Reed 3,004,894 A 10/1961 Johnson et al. (21) Appl. No.: 11/116,761 3,062,715 A 11/1962 Reese 3,067,784. A 12/1962 Gorman 3,092.255. A 6, 1963 Hohman (22) Filed: Apr. 28, 2005 3,092,555 A 6, 1963 Horn 3,141,821 A 7, 1964 Compeau (65) Prior Publication Data 3,142,420 A 7/1964 Gawthrop 3,144,386 A 8/1964 Brighttenback US 2005/0271598 A1 Dec. 8, 2005 3,149,543 A 9, 1964 Naab 3,154,075 A * 10/1964 Weckesser .................... 604/279 3,178,352 A 4, 1965 Erickson Related U.S. Application Data 3,236,457 A 2, 1966 Kennedy et al. 3,244,589 A 4, 1966 Sunnen (63) Continuation-in-part of application No. 10/532,618, 3,252,859 A 5, 1966 Silver filed as application No. PCT/IB03/05527 on Oct. 24, 3,261,695 A 7, 1966 Sienciewicz 2003, application No. 1 1/116,761, which is a 3,263,867 A 8, 1966 Lehmann continuation-in-part of application No. 10/911,367, 3,263,869 A 8, 1966 Corsette filed on Aug. 4, 2004. 3,298.919 A 1/1967 Bishop et al. (60) Provisional application No. 60/429,546, filed on Nov. (Continued) 29, 2002, provisional application No. 60/556,513, FOREIGN PATENT DOCUMENTS filed on Mar. 25, 2004. AU 19878O257 9, 1986 (30) Foreign Application Priority Data AU 7825.15 12/2005 (Continued) Oct. 25, 2002 (IL) .......................................... 1524.86 OTHER PUBLICATIONS Nicol. AIDS 2001, vol. 15 No. 14 pp. 1837-1842.* (51) Int. C. Pendergrass. Gynecol Obstet Invest. 1996:42(3):178-82.* A6 IK 8/00 (2006.01) Kinnunen. Contact Dermatitis. Sep. 1989:21(3): 154-8.* A61O 19/04 (2006.01) International Search Report from PCT/IB2005/004164, mailed Oct. A6 IK 9/12 23, 2006, 7 pages. (2006.01) Barry, B.W. et al. Comparative bio-availability and activity of pro A61O 700 (2006.01) prietary topical corticosteroid preparations: vasoconstrictor assays A61O 19/02 (2006.01) on thirty-one ointments, British Journal of Dermatology, 93, 563 A6 IK 8/60 (2006.01) 571, 1975. A61O 1702 (2006.01) Tamarkin, D., et al. Moisturizing Foam Containing Lanolin, U.S. A6 IK9/00 (2006.01) Appl. No. 1 1/099.942, filed Apr. 6, 2005. A61O 1704 (2006.01) Tamarkin, D., et al. Nonsteroidal Immunomodulating Kit and Com A6 IK9/46 position and Uses Thereof, U.S. Appl. No. 11/078.902, filed Mar. 11, (2006.01) 2005. A6 IK 8/04 (2006.01) Tamarkin, D., etal. Steroid Kit and Foamable Composition and Uses, A61O 702 (2006.01) U.S. Appl. No. 1 1/114,410, filed Apr. 26, 2005. (52) U.S. C. CPC .............. A61K 9/0007 (2013.01); A61O 19/04 (Continued) (2013.01); A61K 9/12 (2013.01); A61O 700 Primary Examiner — Suzanne Ziska (2013.01); A61O 19/02 (2013.01); A61K 8/60 (74) Attorney, Agent, or Firm — Fish & Richardson P.C. (2013.01); A61 K9/122 (2013.01); A61O 1702 (2013.01); A61 K9/0014 (2013.01); A61O (57) ABSTRACT 1704 (2013.01); A61 K 2800/75 (2013.01); The invention relates to an alcohol-free cosmetic ortherapeu A61K 8/046 (2013.01); A61 K9/0034 tic foam carrier comprising water, a hydrophobic organic (2013.01); A61O 702 (2013.01) carrier, a foam adjuvant agent, a Surface-active agent and a USPC ............................................................ 424/47 gelling agent. The cosmetic or therapeutic foam carrier does (58) Field of Classification Search not contain aliphatic alcohols, making it non-irritating and CPC ... A61K 8/046; A61 K9/0014: A61 K9/0034; non-drying. The alcohol-free foam carrier is suitable for A61 K9/12: A61 K9/122 inclusion of both water-soluble and oil soluble therapeutic USPC ............................................................ 424/47 and cosmetic agents. See application file for complete search history. 38 Claims, No Drawings US 8,840,869 B2 Page 2 (56) References Cited 4,305,936 A 12/1981 Klein 4,309,995 A 1/1982 Sacco U.S. PATENT DOCUMENTS 4,310,510 A * 1/1982 Sherman et al. ................ 424/45 4.323,582 A 4/1982 Siegel et al. 3,301,444 A 1, 1967 Wittke 4.323,694. A 4, 1982 Scala, Jr. 3,303,970 A 2f1967 Breslau et al. 4.325,939 A 4, 1982 Shah 3,330,730 A 7, 1967 Hernandez 4.329,990 A 5/1982 Sneider 3,333,333 A 8, 1967 Noack 4,335,120 A 6, 1982 Holicket al. 3,334,147 A 8, 1967 Brunelle et al. 4,352,808 A 10, 1982 Rane et al. 3,346,451 A 10/1967 Collins et al. 4.385,161 A 5/1983 Caunt et al. 3,366,494. A 1, 1968 Bower et al. 4,386,104 A 5/1983 Nazzaro-Porro 3,369,034 A 2f1968 Chalmers 4,393,066 A 7/1983 Garrett et al. 3,377,004 A 4, 1968 Wittke 4.427,670 A 1/1984 Ofuchi et al. 3,384.541 A 5, 1968 Clarket al. 4,439,416 A 3, 1984 Cordon et al. 3,395.214 A 7, 1968 Mummert 4,439,441 A 3/1984 Hallesy et al. 3.395.25 A 7, 1968 Schubert 4,440,320 A 4, 1984 Wernicke 3,401,849 A 9/1968 Weber, III 4,447.486 A 5/1984 Hoppe et al. 3.419,658 A 12/1968 Sanders 4,469,674. A 9, 1984 Shah et al. 3.456,052 A 7, 1969 Gordon 4,508,705 A 4, 1985 Chaudhuri et al. 3,527,559 A 9, 1970 Sliwinski 4,522,948 A 6, 1985 Walker 3,540,448 A 11, 1970 Sunnen 4,529,601 A 7/1985 Broberg et al. 3,559,890 A 2f1971 Brooks et al. 4,529,605 A 7/1985 Lynch et al. 3,561,262 A 2f1971 Borucki 4,552,872 A 1 1/1985 Cooper et al. 3,563,098 A 2/1971 Weber, III 4,574,052 A 3/1986 Gupte et al. 3,574,821 A 4, 1971 Pfirrmann 4,576,961 A 3, 1986 Lorck et al. 3,577,518 A 5/1971 Shepherd 4,595,526 A 6, 1986 Lai 3.667.461 A 6, 1972 Zamarra 4,603,812 A 8, 1986 Stoesser et al. 3.751562 A 8, 1973 Nichols 4,627,973 A 12/1986 Moran et al. 3,770,648 A 11, 1973 Mackles 4,628,063 A 12/1986 Haines et al. 3,787,566 A 1/1974 Gauvreau 4,661.524. A 4, 1987 Thomson et al. 3,819,524 A 6, 1974 Schubert et al. 4,672,078 A 6, 1987 Sakai et al. 3,841,525 A 10/1974 Siegel 4,673,569 A 6, 1987 Shernov et al. 3,849,580 A 1 1/1974 Weinstein et al. 4,678,463 A 7, 1987 Millar 3.865.275 A 2f1975 De Nunzio 4,701,320 A 10/1987 Hasegawa et al. 3.866,800 A 2, 1975 Schmitt 4,725,609 A 2/1988 Kull, Jr. et al. 3,882,228 A 5/1975 Boncey et al. 4,738,396 A 4, 1988 Doi et al. 3,886,084 A 5, 1975 Vassiliades 4,741,855 A 5, 1988 Grote et al. 3,890,305 A 6, 1975 Weber et al. 4,752.465 A 6, 1988 Mackles 3,912,665 A 10/1975 Spitzer et al. 4,770,634 A 9, 1988 Pelico 3,923,970 A 12/1975 Breuer 4,772,427 A 9, 1988 Dawson 3,929,985 A * 12/1975 Webb, Jr. ........................ 424/45 4,780,309 A 10/1988 Geria et al. 3,952,916 A 4/1976 Phillips 4,784.842 A 11/1988 London et al. 3,959,160 A 5, 1976 Horsler et al. 4,792,062. A 12/1988 Goncalves 3,962,150 A 6, 1976 Viola 4,798,682 A 1, 1989 Ansmann 3,963,833. A 6, 1976 DeSalva et al. 4,804.674. A * 2/1989 Curtis-Prior et al. ......... 514,400 3,966,090 A 6, 1976 Prussin et al. 4,806,262 A 2/1989 Snyder 3,966,632 A 6/1976 Colliopoulos et al. 4,808,388 A 2f1989 Beutler et al. 3,970,219 A 7/1976 Spitzer et al. 4,822,613 A 4, 1989 Rodero 3,970,584 A 7, 1976 Hart et al. 4,822,614 A 4, 1989 Rodero 3,993,224 A 11, 1976 Harrison 4,826,048 A 5/1989 Skorka et al. 3,997.467 A 12/1976 Jederstrom 4,827,378 A 5/1989 Gillan et al.
Load more

Recommended publications
  • De Novo Sequencing and Analysis of the American Ginseng Root
    Sun et al. BMC Genomics 2010, 11:262 http://www.biomedcentral.com/1471-2164/11/262 RESEARCH ARTICLE Open Access DeResearch novo article sequencing and analysis of the American ginseng root transcriptome using a GS FLX Titanium platform to discover putative genes involved in ginsenoside biosynthesis Chao Sun†1, Ying Li†1, Qiong Wu1, Hongmei Luo1, Yongzhen Sun1, Jingyuan Song1, Edmund MK Lui2 and Shilin Chen*1 Abstract Background: American ginseng (Panax quinquefolius L.) is one of the most widely used herbal remedies in the world. Its major bioactive constituents are the triterpene saponins known as ginsenosides. However, little is known about ginsenoside biosynthesis in American ginseng, especially the late steps of the pathway. Results: In this study, a one-quarter 454 sequencing run produced 209,747 high-quality reads with an average sequence length of 427 bases. De novo assembly generated 31,088 unique sequences containing 16,592 contigs and 14,496 singletons. About 93.1% of the high-quality reads were assembled into contigs with an average 8-fold coverage. A total of 21,684 (69.8%) unique sequences were annotated by a BLAST similarity search against four public sequence databases, and 4,097 of the unique sequences were assigned to specific metabolic pathways by the Kyoto Encyclopedia of Genes and Genomes. Based on the bioinformatic analysis described above, we found all of the known enzymes involved in ginsenoside backbone synthesis, starting from acetyl-CoA via the isoprenoid pathway. Additionally, a total of 150 cytochrome P450 (CYP450) and 235 glycosyltransferase unique sequences were found in the 454 cDNA library, some of which encode enzymes responsible for the conversion of the ginsenoside backbone into the various ginsenosides.
    [Show full text]
  • On Skin Cells and Mitochondria Isolated from Melanoma Induced Mouse
    Original Research Article 2019;2(1):e5 Selective Toxicity of Standardized Extracts of Persian Gulf Sponge (Irciniamutans) on Skin Cells and Mitochondria isolated from Melanoma induced mouse a b c d e Yalda Arast , Nina SeyedRazi , Melika Nazemi , Enayatollah Seydi , Jalal Pourahmad * a. Department of Occupational Health Engineering, Faculty of Health, Qom University of Medical Sciences, Qom, Iran. b. Pharmaceutical Sciences Research Center, ShahidBeheshti University of Medical Sciences, Tehran, Iran. c. Persian Gulf and Oman Sea Ecological Center, Iranian Fisheries Science Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Bandar Abbas, Iran. d. Research Center for Health, Safety and Environment (RCHSE), Department of Occupational Health Engineering, Alborz University of Medical Sciences, Karaj, Iran. e. Department of Pharmacology and Toxicology, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Article Info: ABSTRACT: Received: March 2019 Melanoma is an aggressive and highly lethal cancer with poor prognosis and Accepted: June 2019 resistance to current treatments. Apoptosis signaling is believed to be suppressed in Published online: melanoma. Evidence suggests that compounds isolated from marine sponges have June 2019 anti-cancer properties. This study was designed to evaluate the apoptotic effect of methanolic, diethyl ether, and n-hexane extracts of Irciniamutans (I.mutans) on skin mitochondria isolated from mice animal
    [Show full text]
  • A Comprehensive Review on Phyllanthus Derived Natural Products As Potential Chemotherapeutic and Immunomodulators for a Wide Range of T Human Diseases
    Biocatalysis and Agricultural Biotechnology 17 (2019) 529–537 Contents lists available at ScienceDirect Biocatalysis and Agricultural Biotechnology journal homepage: www.elsevier.com/locate/bab A comprehensive review on Phyllanthus derived natural products as potential chemotherapeutic and immunomodulators for a wide range of T human diseases Mohamed Ali Seyed Department of Clinical Biochemistry, Faculty of Medicine, University of Tabuk, Tabuk 71491, Saudi Arabia ARTICLE INFO ABSTRACT Keywords: Treatment options for most cancers are still insufficient, despite developments and technology advancements. It Cancer has been postulated that the immune response to progressive tumors is insufficient due to a deficiency in afferent Phyllanthus amarus/niruri mechanisms responsible for the development of tumor-reactive T cells. Many patients treated for cancer will Phyllanthin have their cancer recurrence, often after a long remission period. This suggests that there are a small number of Hypophyllanthin tumor cells that remain alive after standard treatment(s) – alone or in combination and have been less effective Chemotherapeutic in combating metastasis that represents the most elaborate hurdle to overcome in the cure of the disease. Immunomodulation Therefore, any new effective and safe therapeutic agents will be highly demanded. To circumvent many plant extracts have attributed for their chemoprotective potentials and their influence on the human immune system. It is now well recognized that immunomodulation of immune response could provide an alternative or addition to conventional chemotherapy for a variety of disease conditions. However, many hurdles still exist. In recent years, there has been a tremendous interest either in harnessing the immune system or towards plant-derived immunomodulators as anticancer agents for their efficacy, safety and their targeted drug action and drug de- livery mechanisms.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin Et Al
    USOO8486374B2 (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin et al. (45) Date of Patent: Jul. 16, 2013 (54) HYDROPHILIC, NON-AQUEOUS (56) References Cited PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES U.S. PATENT DOCUMENTS 1,159,250 A 11/1915 Moulton 1,666,684 A 4, 1928 Carstens (75) Inventors: Dov Tamarkin, Maccabim (IL); Meir 1924,972 A 8, 1933 Beckert Eini, Ness Ziona (IL); Doron Friedman, 2,085,733. A T. 1937 Bird Karmei Yosef (IL); Alex Besonov, 2,390,921 A 12, 1945 Clark Rehovot (IL); David Schuz. Moshav 2,524,590 A 10, 1950 Boe Gimzu (IL); Tal Berman, Rishon 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely LeZiyyon (IL); Jorge Danziger, Rishom 2,767,712 A 10, 1956 Waterman LeZion (IL); Rita Keynan, Rehovot (IL); 2.968,628 A 1/1961 Reed Ella Zlatkis, Rehovot (IL) 3,004,894 A 10/1961 Johnson et al. 3,062,715 A 11/1962 Reese et al. 3,067,784. A 12/1962 Gorman (73) Assignee: Foamix Ltd., Rehovot (IL) 3,092.255. A 6, 1963 Hohman 3,092,555 A 6, 1963 Horn 3,141,821 A 7, 1964 Compeau (*) Notice: Subject to any disclaimer, the term of this 3,142,420 A 7/1964 Gawthrop patent is extended or adjusted under 35 3,144,386 A 8/1964 Brightenback U.S.C. 154(b) by 1180 days. 3,149,543 A 9, 1964 Naab 3,154,075 A 10, 1964 Weckesser 3,178,352 A 4, 1965 Erickson (21) Appl.
    [Show full text]
  • Alternative Treatments for Cancer Prevention and Cure [Part 1]
    Advances in Pharmacology and Clinical Trials ISSN: 2474-9214 Alternative Treatments for Cancer Prevention and Cure [Part 1] Abdul Kader Mohiuddin* Review Article Secretary & Treasurer Dr M. Nasirullah Memorial Trust, Tejgaon, Dhaka, Bangladesh Volume 4 Issue 4 Received Date: September 02, 2019 *Corresponding author: Abdul Kader Mohiuddin, Secretary & Treasurer Dr M Published Date: October 17, 2019 Nasirullah Memorial Trust, Tejgaon, Dhaka, Bangladesh, Tel: +8802-9110553; Email: DOI: 10.23880/apct-16000168 [email protected] Abstract Many lay people along with some so called “key opinion leaders” have a common slogan “There's no answer for cancer”. Again, mistake delays proper treatment and make situation worse, more often. Compliance is crucial to obtain optimal health outcomes, such as cure or improvement in QoL. Patients may delay treatment or fail to seek care because of high out-of- pocket expenditures. Despite phenomenal development, conventional therapy falls short in cancer management. There are two major hurdles in anticancer drug development: dose-limiting toxic side effects that reduce either drug effectiveness or the QoL of patients and complicated drug development processes that are costly and time consuming. Cancer patients are increasingly seeking out alternative medicine and might be reluctant to disclose its use to their oncology treatment physicians. But there is limited available information on patterns of utilization and efficacy of alternative medicine for patients with cancer. As adjuvant therapy, many traditional medicines shown efficacy against brain, head and neck, skin, breast, liver, pancreas, kidney, bladder, prostate, colon and blood cancers. The literature reviews non-pharmacological interventions used against cancer, published trials, systematic reviews and meta-analyses.
    [Show full text]
  • American Journal of Biological and Pharmaceutical Research
    Leon Stephan Raj T. et al. / American Journal of Biological and Pharmaceutical Research. 2015;2(4):161-167. e-ISSN - 2348-2184 Print ISSN - 2348-2176 AMERICAN JOURNAL OF BIOLOGICAL AND PHARMACEUTICAL RESEARCH Journal homepage: www.mcmed.us/journal/ajbpr QUALITATIVE AND QUANTITATIVE ANALYSIS OF PHYTOCONSTITUENTS OF MICROCOCCA MERCURIALIS. (L.) BENTH. T. Leon Stephan Raj1* A. Antony Selvi1, P. Ramakrishnan1, M. Antony Fency1 M. Vellakani1 and D. Vanila2 1Department of Botany, St. Xavier’s College (Autonomous), Palayamkottai. Tamil Nadu, India. 2Department of Botany, TDMNS College, T. Kallikulam. Tamil Nadu, India. Article Info ABSTRACT Received 29/08/2015 Plants are the chemical factories consist of lots of phytochemicals. Phytochemical are Revised 16/09/2015 primary and secondary metabolites have some medicinal values and plays an important role Accepted 19/10/2015 in internal mechanisms of plants. The present study was aimed at qualitative and quantitative analysis of phytoconstituents of Micrococca mercurialis (L.) Benth. leaf, stem, Key words: - root and fruit. The shade dried parts of the plant powder were subjected to successive Micrococca Soxhlet extraction using petroleum ether, benzene, chloroform, methanol and water. These mercurialis, solvent extracts were subjected to the preliminary phytochemical screening to detect the Phytochemical analysis, different chemical principles present in the plant. The phytochemical analysis revealed the Metabolites, Medicinal presence of alkaloids, saponins, tannins, flavonoids, terpenoids, quinines, glycosides, plants. steroids, phenols in varying concentrations. The present study provides evidence that solvent extract of Micrococca mercurialis contains medicinally important bioactive compounds and this justifies the use of plant species as traditional medicine for treatment of various diseases. INTRODUCTION Nature has been a source of medicinal agents since The use of plant whether herbs, shrubs or tree, in times immemorial.
    [Show full text]
  • Investigating Labdane-Related Diterpenoids Biosynthetic Network In
    Iowa State University Capstones, Theses and Graduate Theses and Dissertations Dissertations 2012 Investigating labdane-related diterpenoids biosynthetic network in rice: characterization of cytochromes P450 and short-chain alcohol dehydrogenases/reductase Yisheng Wu Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/etd Part of the Biochemistry Commons Recommended Citation Wu, Yisheng, "Investigating labdane-related diterpenoids biosynthetic network in rice: characterization of cytochromes P450 and short-chain alcohol dehydrogenases/reductase" (2012). Graduate Theses and Dissertations. 12680. https://lib.dr.iastate.edu/etd/12680 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Investigating labdane-related diterpenoids biosynthetic network in rice: Characterization of cytochromes P450 and short-chain alcohol dehydrogenases/reductase by Yisheng Wu A dissertation submitted to the graduate faculty in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Major: Biochemistry Program of Study Committee: Reuben Peters, Major Professor Gustavo MacIntosh Thomas Bobik Bing Yang Mark Hargrove Iowa State University Ames, Iowa 2012 Copyright © Yisheng Wu , 2012. All
    [Show full text]
  • The Effects of Foods on Blood Lipids in Non-Alcoholic Fatty Liver Disease (NAFLD)—A Systematic Review and Meta-Analysis
    SYSTEMATIC REVIEW published: 16 December 2020 doi: 10.3389/fnut.2020.613221 The Effects of Foods on Blood Lipids in Non-alcoholic Fatty Liver Disease (NAFLD)—A Systematic Review and Meta-Analysis Fredrik Rosqvist 1, Andreas Rydell 2,3 and David Iggman 1,2* 1 Clinical Nutrition and Metabolism, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden, 2 Norslund-Svärdsjö Academic Health Care Center, Center for Clinical Research Dalarna, Falun, Sweden, 3 Division of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institute, Huddinge, Sweden Background: Non-alcoholic fatty liver disease (NAFLD) is associated with dyslipidemia and increased cardiovascular disease risk. Dietary choices may produce profound effects Edited by: on blood lipids. Thus, the purpose of this study was to investigate which foods modify Anne Marie Minihane, blood lipids in NAFLD. University of East Anglia, United Kingdom Methods: Systematic review of published systematic reviews and randomized Reviewed by: controlled trials (RCTs). Searches were performed in PubMed, Cochrane Database of Wendy Louise Hall, King’s College London, Systematic Reviews, and Cochrane Central Register of Controlled Trials, from inception United Kingdom through March 2020. Studies in populations with NAFLD, which provided data on Amalia Gastaldelli, foods or dietary patterns and blood lipids were included, but not weight loss diets, National Research Council (CNR), Italy supplements, nor individual nutrients. The strength of evidence was evaluated using The *Correspondence: David Iggman Grading of Recommendations Assessment, Development, and Evaluation (GRADE). [email protected] Results: No relevant systematic reviews were identified. Eleven RCTs were included Specialty section: in the qualitative synthesis.
    [Show full text]
  • Report Name: Agricultural Biotechnology Annual - 2020
    Required Report: Required - Public Distribution Date: November 06,2020 Report Number: IS2020-0015 Report Name: Agricultural Biotechnology Annual - 2020 Country: Israel Post: Tel Aviv Report Category: Biotechnology and Other New Production Technologies Prepared By: Jessica Sullum-Shay, Agricultural Marketing Specialist and Mariano J. Beillard, Senior Regional Agricultural Attaché Approved By: Ali Abdi, Minister-Counselor for Agricultural Affairs Report Highlights: As of September 2020, Israel does not have a policy restricting the use of imported genetically engineered (GE) commodities or derivative products. There are no changes in Israel’s policy towards plant and animal biotechnology compared to 2019. A new section on microbial biotechnology has been added to the report. THIS REPORT CONTAINS ASSESSMENTS OF COMMODITY AND TRADE ISSUES MADE BY USDA STAFF AND NOT NECESSARILY STATEMENTS OF OFFICIAL U.S. GOVERNMENT POLICY EXECUTIVE SUMMARY As of September 2020, Israel does not have a policy restricting the use of imported genetically engineered (GE) commodities or derivative products. Israel’s 2005 “Seed Regulation for Plants and Other GE Organisms” (GE Seed Regulation) states that the sale of GE crops is not permissible without a valid Registration Certificate. In Israel, GE crop production is allowed for research purposes. Regulations allow GE commodities and products to be imported, sold, and used for food and feed production, as well as for ornamental and pharmaceutical uses. Israel’s Kashrut (religious authority) determined that the use of GE ingredients in food does not affect its kosher status as these ingredients are used in “microscopic” proportions. Currently, the volume of products of agricultural biotechnology (biotech) imports to Israel is not quantified and domestic experimental use is limited.
    [Show full text]
  • Universidade De São Paulo Instituto De Química De São Paulo Química Orgânica E Biológica
    UNIVERSIDADE DE SÃO PAULO INSTITUTO DE QUÍMICA DE SÃO PAULO QUÍMICA ORGÂNICA E BIOLÓGICA MARCELO TAVARES DE OLIVEIRA QUANTUM CHEMICAL EXPLORATIONS INTO THE BIOSYNTHESIS OF PENTACYCLIC TRITERPENE FRIEDELIN TESE DE DOUTORADO SÃO CARLOS 2019 MARCELO TAVARES DE OLIVEIRA QUANTUM CHEMICAL EXPLORATIONS INTO THE BIOSYNTHESIS OF PENTACYCLIC TRITERPENE FRIEDELIN Tese apresentada ao Instituto de Química de São Carlos da Universidade de São Paulo como parte dos requisitos para a obtenção do título de doutor em ciências Área de concentração: Química Orgânica e Biológica Orientador: Prof. Dr. Albérico B. F. da Silva SÃO CARLOS 2019 To Sarah. Acknowledgments Firstly, I wish to express my sincere thanks to Prof. Albérico for facilitating “in his very own way” the work described here in the course of the past year and a half. I thank Prof. Ataualpa Braga (IQ/USP) for his most helpful discussions on methods, especially the tweaks of gaussian. Prof. Glaucius Oliva (IFSC/USP) is acknowledged for his precious contribution towards the zeitgeist workstation where most computations were carried out. Mr. Gilmar Bertollo Jr. (IFSC/USP), a very knowledgeable tech guy, for his great assistance with hardware – very appreciated. I express my gratitude to all colleagues (and a few new friends) as well as all members of the community at large in the chemistry institute (IQSC/USP) and the physics institute (IFSC/USP). To all those I came across over the past few years of postgraduate studies who had a share of contribution to make things easier somehow. The Coordination for the Improvement of Higher Education Personnel, CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) is acknowledged for an institutional studentship.
    [Show full text]
  • Regulation of the Abscisic Acid Response by Protein Phosphatase 2C-Interacting Proteins ABP7 and ABP9 in Arabidopsis Thaliana
    Technische Universität München Lehrstuhl für Botanik Regulation of the abscisic acid response by protein phosphatase 2C-interacting proteins ABP7 and ABP9 in Arabidopsis thaliana Yue Ma-Lauer Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzender: Univ.-Prof. Dr. R. Hückelhoven Prüfer der Dissertation: 1. Univ.-Prof. Dr. E. Grill 2. apl. Prof. Dr. R. A. Torres Ruiz Die Dissertation wurde am 07.12.2010 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 21.03.2011 angenommen. Content Content Abbreviations................................................................................................ 1 Summary ....................................................................................................... 6 Zusammenfassung ....................................................................................... 9 1. Introduction............................................................................................. 12 1.1 ABA signal ........................................................................................... 12 1.2 Pathogenesis-Related Proteins ......................................................... 24 1.3 The family of ABP7 and ABP9 in Arabidopsis thaliana ......................... 30 1.4 The aim of this
    [Show full text]
  • Drug/Substance Trade Name(S)
    A B C D E F G H I J K 1 Drug/Substance Trade Name(s) Drug Class Existing Penalty Class Special Notation T1:Doping/Endangerment Level T2: Mismanagement Level Comments Methylenedioxypyrovalerone is a stimulant of the cathinone class which acts as a 3,4-methylenedioxypyprovaleroneMDPV, “bath salts” norepinephrine-dopamine reuptake inhibitor. It was first developed in the 1960s by a team at 1 A Yes A A 2 Boehringer Ingelheim. No 3 Alfentanil Alfenta Narcotic used to control pain and keep patients asleep during surgery. 1 A Yes A No A Aminoxafen, Aminorex is a weight loss stimulant drug. It was withdrawn from the market after it was found Aminorex Aminoxaphen, Apiquel, to cause pulmonary hypertension. 1 A Yes A A 4 McN-742, Menocil No Amphetamine is a potent central nervous system stimulant that is used in the treatment of Amphetamine Speed, Upper 1 A Yes A A 5 attention deficit hyperactivity disorder, narcolepsy, and obesity. No Anileridine is a synthetic analgesic drug and is a member of the piperidine class of analgesic Anileridine Leritine 1 A Yes A A 6 agents developed by Merck & Co. in the 1950s. No Dopamine promoter used to treat loss of muscle movement control caused by Parkinson's Apomorphine Apokyn, Ixense 1 A Yes A A 7 disease. No Recreational drug with euphoriant and stimulant properties. The effects produced by BZP are comparable to those produced by amphetamine. It is often claimed that BZP was originally Benzylpiperazine BZP 1 A Yes A A synthesized as a potential antihelminthic (anti-parasitic) agent for use in farm animals.
    [Show full text]